Imaging technologies maximize the value of orthotopic and metastatic modeling in xenograft models in many ways, including real-time and spatial tracking of disease progression. Additionally, new techniques using high-frequency ultrasound are improving the establishment of organ-specific orthotopic models.
In this webinar, the final installment of our Tech Talk series, In Vivo Solutions for Oncology Drug Development, Dr. Yinfei Yin presents the advantages of using orthotopic and metastatic models for preclinical studies and how establishment of xenograft models can be improved through optical imaging and high-frequency ultrasound.
Yinfei Yin, PhD, Executive Director, Head of Scientific Operations, UK & US, Crown Bioscience
Dr. Yinfei Yin is leading the Scientific Operations team at Crown Bioscience’s UK & US sites and also the head of Crown’s Global Imaging Platform. Yinfei has worked with the team in developing and delivering a portfolio of in vivo projects to the highest scientific standards, using a wide range of in vivo models such as metastasis, orthotopic and traditional subcutaneous models - to support key client decisions and successful drug discovery programmes. Prior to joining Crown Bioscience, Yinfei worked at the University of Nottingham’s Ex Vivo Cancer Pharmacology Centre of Excellence in development of a bioluminescence and fluorescence-aided pharmaceutical candidate validation platform. Yinfei received his PhD from the University of Nottingham working on the role of Helicobacter pylori-stimulated EGF receptor in cancer invasion and metastasis.